Trial Information

Summary: Quantitative Determination of Substance P Concentrations in Blood, Saliva, and Urine of Patients Receiving Chemotherapy of Moderate to High Emetogenic Potential (Aprepitant)

• To profile the time course of SP during the early and delayed phases of CINV by analyzing serum, saliva and possibly urine peptide levels. Experiments related to this specific aim will measure SP levels from three sources during and after chemotherapy.
• To determine whether SP and 5-HIAA levels correlate with timing and emetogenic potential of chemotherapy. Emetogenicity of various agents and combinations have already been established with which clinical correlations with specific receptor antagonists can now be made.

Patient Inclusion Criteria

• Who have a histologic diagnosis of a malignant solid neoplasm, primarily, although not restricted to carcinomas of the bladder, esophagus, or breast.
• Who will receive cisplatin-based chemotherapy or chemotherapy regimens determined to have high or moderately high emetogenic (eg, paclitaxel/carboplatin) potential for the first time.
• Who have disease of any stage that requires treatment according to current established standards of care.
• Who have a performance status (EGOG) of 2 or less.
• Who have intact organ function as determined by laboratory tests of the kidney, liver, and bone marrow deemed appropriate to receive cytotoxic therapy.
• Who are 18 years of age or older.
• Not restricted by gender or ethnicity.
• Who have signed an informed consent to participate in this study.

See www.hsc.wvu.edu/mbrcc/ctru/ for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 6:31:31 AM